Clinical trials: HIV Treatment Adherence
HIV Infections
Observational Study of Nevirapine Extended Release in Human Immunodeficiency Virus (HIV) Patients in Daily Clinical Practice
This Post Marketing Surveillance study will be performed as an open-label, prospective, non-interventional, uncontrolled study in Human immunodeficit Virus-1 (HIV-1) infected patients.
- Trial name
- NCT01524900
- Where
- 53 sites in Austria, Poland and 1 more
- Volunteers
- 398 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
This is a 90-day medication adherence study testing the HiDO is an automated AI-driven direct observation medication adherence platform, which is a 510K-exempt, Class I medical device with 24 people with HIV/AIDS, ages 18 to 55…
- Trial name
- NCT05454514
- Testing
- HiDO medication adherence platform, Automated Medication Platform with Video Observation, Time on Task
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Charles Gellman
HIV Infection
Study of Adherence Effects and Clinical Outcomes of Kaletra Based HIV Antiviral Therapy
The purpose of this study is to evaluate the effects of adherence on HIV antiviral response to treatment regimens containing Kaletra or other HIV protease inhibitors.
- Trial name
- NCT00234962
- Testing
- Lopinavir/Ritonavir
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abbott
Human Immunodeficiency Virus Infection
Treatment Perception of QD (Once a Day) Dosed Kaletra (Tablets)
Both twice-a-day (BID) and once-a-day (QD) dosing are approved in Europe for the protease inhibitor lopinavir/ritonavir (LPV/r; Kaletra®).
- Trial name
- QD-Kapital (NCT01383005)
- Where
- 20 sites in Spain
- Volunteers
- 97 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
HIV Infections
Safety Study of Once a Day ART and Opiate Substitute.
This study looks at HIV-infected subjects who are on methadone treatment and medicines for HIV.
- Trial name
- 3OD (NCT00324688)
- Testing
- Viread
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
- Trial name
- NCT00002217
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Infection, Human Immunodeficiency Virus, HIV Infections
A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects
This study is a Phase IIb, randomized, multicentre, parallel group, open-label, study having an overall objective to evaluate the antiviral activity, tolerability, and safety of two intramuscular (IM) dosing regimens of GSK744 LA…
- Trial name
- NCT02120352
- Testing
- CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 309 people
- Sponsor
- ViiV Healthcare
HIV Infections
The Effect of Teaching HIV-Infected Patients About HIV and Treatment
The purpose of this study is to see if an HIV-education course can help under-represented, HIV-infected patients. This study examines the areas of faithfulness to drug regimen, level of HIV in the blood, and health status.
- Trial name
- NCT00002409
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Glaxo Wellcome
HIV
A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence
PRO 140 2102 is a phase 2b, national, multicenter, randomized, double-blind, placebo-controlled study in order to evaluate the safety and efficacy of PRO 140 (anti-CCR5 monoclonal antibody) administered subcutaneously as an…
- Trial name
- NCT01272258
- Testing
- PRO 140
- Where
- United States
- Sponsor
- CytoDyn, Inc.
HIV Infections
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
To determine the safety and efficacy of a simple, once-daily antiretroviral (ARV) regimen consisting of a fixed-dose combination tablet containing Truvada combined with atazanavir boosted with ritonavir in treatment naive…
- Trial name
- NCT00224445
- Testing
- Truvada, Atazanavir, Ritonavir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study of Two Anti-HIV Drug Combinations
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI.
- Trial name
- NCT00002203
- Testing
- Lamivudine/Zidovudine, Lamivudine, Zidovudine
- Where
- 7 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
HIV/AIDS, HIV Infections
Harm Reduction Program For Informal PrEP Users In A Community-based Setting (seguiPrEP)
Pre-Exposure Prophylaxis (PrEP) is a biomedical strategy consisting of the use of antiretroviral therapy by HIV-seronegative people at high risk of acquiring HIV, to prevent the infection.
- Conditions
- HIV/AIDS, HIV Infections, Sexually Transmitted Diseases, Vaccination
- Trial name
- seguiPrEP (NCT03996941)
- Testing
- Harm reduction of informal PrEP use, PrEP follow up based on point of care testing
- Where
- Spain
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- BCN Checkpoint